Affiliation:
1. Department of Internal Medicine , Cleveland Clinic Foundation , Cleveland , OH , USA
2. Department of Nephrology and Hypertension, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University , Cleveland , OH , USA
Abstract
Abstract
Chronic kidney disease (CKD) affects approximately 15% of the US population and is associated with significant cardiovascular morbidity and mortality. The two leading causes of end stage kidney disease are hypertension and diabetes mellitus, both of which are modifiable risk factors. The cornerstones of CKD care include early detection, management of associated risk factors, modification of cardiovascular disease risk, slowing progression of disease, and management of complications including anemia, acid base disturbance, and mineral and bone disorders. For the last 20 years, renin-angiotensin system inhibitors were the mainstay treatment for proteinuric diabetic and nondiabetic kidney disease. Recently, new therapies such as sodium-glucose linked transporter 2 inhibitors, have emerged as powerful tools in the treatment of CKD with indications in both diabetic and nondiabetic kidney disease. In this article, we define CKD staging, review new hypertension and diabetic guidelines for CKD patients, and discuss major trials for new potential therapies in CKD, particularly diabetic kidney disease. We will provide practical guidance for primary care physicians to diagnose CKD and implement these agents early in the disease course to prevent the progression of disease and reduce the morbidity and mortality of this vulnerable population.
Subject
Complementary and alternative medicine,Complementary and Manual Therapy
Reference53 articles.
1. United States Renal Data System. USRDS annual data report: epidemiology of kidney disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2020.
2. Keith, DS, Nichols, GA, Gullion, CM, Brown, JB, Smith, DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004;164:659–63. https://doi.org/10.1001/archinte.164.6.659.
3. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013;3:1–150.
4. Go, AS, Chertow, GM, Fan, D, McCulloch, CE, Hsu, C. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296–305. https://doi.org/10.1056/nejmoa041031.
5. Tseng, CL. Survival benefit of nephrologic care in patients with diabetes mellitus and chronic kidney disease. Arch Intern Med 2008;168:55. https://doi.org/10.1001/archinternmed.2007.9.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献